Related Experiment Video

Updated: May 4, 2026

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

1.9K

Should GLP-1 receptor agonists be used with caution in high risk population for colorectal cancer?

Yang Sun1, Lei Fan1, Jin Meng2

  • 1Key Laboratory of Gastrointestinal Pharmacology of Chinese Materia Medica of the State Administration of Traditional Chinese Medicine, Department of Pharmacology, School of Pharmacy, Fourth Military Medical University, Xi'an 710032, Shaanxi, PR China.

Medical Hypotheses
|January 16, 2014
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) receptor agonists show promise for diabetes treatment. However, their influence on the Wnt/β-catenin pathway may elevate colorectal cancer risk.

Area of Science:

  • Endocrinology
  • Oncology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 (GLP-1) receptor agonists are emerging anti-diabetic medications with a favorable side effect profile.
  • These drugs are widely anticipated by clinicians and patients for diabetes management.
  • Long-term clinical use is limited, raising concerns about potential unknown adverse effects.

Purpose of the Study:

  • To investigate the potential association between GLP-1 receptor agonist use and an increased risk of colorectal cancer.
  • To explore the mechanistic link between GLP-1 receptor agonists, the Wnt/β-catenin pathway, and colorectal tumorigenesis.

Main Methods:

  • The study hypothesizes a potential link based on the known effects of GLP-1 receptor agonists.
  • The mechanism involves the enhancement of pancreatic β-cell proliferation via the Wnt/β-catenin pathway.
  • This pathway is also implicated in the development of colon cancer.

Main Results:

  • GLP-1 receptor agonists influence the Wnt/β-catenin pathway.
  • The Wnt/β-catenin pathway is associated with colorectal cancer development.
  • A potential increased risk for colorectal cancer is hypothesized.

Conclusions:

  • GLP-1 receptor agonists may pose a risk for colorectal cancer due to their effect on the Wnt/β-catenin pathway.
  • Further research is warranted to confirm this potential adverse effect.
  • The long-term safety of GLP-1 receptor agonists requires ongoing evaluation.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.6K
Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer05:30

Laparoscopic Radical Gastrectomy for Remnant Gastric Cancer

Published on: October 31, 2025

459

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
993
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
953
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists01:23

Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists

Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
1.4K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
1.0K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
1.1K